TOM Medications concludes another round of funding at over CHF 1.3 million
Summary
The latest round of funding for TOM Medications was hugely oversubscribed, at CHF 1.3 million, or over 120 percent. As the recent round of funding showed, investors believe there is plenty more potential in the virtual medicine cabinet: it was massively oversubscribed, at over CHF 1.3 million, or more than 120 percent.Due to tangible success in 2022, the majority of previous investors were immediately willing to reinvest, says TOM founder and CEO Sven Beichler. Following the successful implementation of the joint pilot project, were happy to continue supporting TOM Medications in its development. Were also delighted that Galenica is now on board, too, says Sanitas CEO Dr. Andreas Sch\xf6nenberger.Galenica was impressed by TOMs existing investors, as well as its forward-looking concept. Thats why we chose to get on board with TOM, says Daniele Madonna, Chief Healthcare Officer at Galenica AG.Boosting turnover, growing the community, and expanding into GermanyThe new resources allow TOM Medications to make its plans a reality: We want to keep growing our customer base as well as our turnover, too, adds Sven Beichler.